Sight Sciences (NASDAQ:SGHT) CFO James Rodberg Sells 2,616 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CFO James Rodberg sold 2,616 shares of Sight Sciences stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $6.62, for a total value of $17,317.92. Following the completion of the transaction, the chief financial officer directly owned 151,230 shares of the company’s stock, valued at $1,001,142.60. This represents a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

James Rodberg also recently made the following trade(s):

• On Tuesday, January 6th, James Rodberg sold 594 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total transaction of $4,443.12.
• On Monday, January 5th, James Rodberg sold 4,405 shares of Sight Sciences stock. The shares were sold at an average price of $7.82, for a total transaction of $34,447.10.

Sight Sciences Stock Up 2.2%

Shares of NASDAQ:SGHT opened at $6.38 on Thursday. The company has a 50 day moving average price of $7.78 and a two-hundred day moving average price of $5.33. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.93 and a current ratio of 9.60. The company has a market capitalization of $337.31 million, a PE ratio of -7.09 and a beta of 2.42. Sight Sciences, Inc. has a 52 week low of $2.03 and a 52 week high of $9.24.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.10. The company had revenue of $19.91 million during the quarter, compared to analysts’ expectations of $17.74 million. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%. Analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Institutional Trading of Sight Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of SGHT. Palumbo Wealth Management LLC bought a new position in shares of Sight Sciences in the fourth quarter valued at approximately $294,000. Long Focus Capital Management LLC boosted its holdings in Sight Sciences by 1.3% during the 3rd quarter. Long Focus Capital Management LLC now owns 3,193,305 shares of the company’s stock worth $10,985,000 after acquiring an additional 41,797 shares during the last quarter. Millennium Management LLC grew its stake in shares of Sight Sciences by 145.2% in the 3rd quarter. Millennium Management LLC now owns 133,846 shares of the company’s stock worth $460,000 after acquiring an additional 79,265 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of Sight Sciences by 5.5% in the third quarter. Alliancebernstein L.P. now owns 34,380 shares of the company’s stock valued at $118,000 after purchasing an additional 1,800 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in Sight Sciences by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after purchasing an additional 3,785 shares during the last quarter. Institutional investors own 55.51% of the company’s stock.

Wall Street Analyst Weigh In

SGHT has been the topic of several analyst reports. Morgan Stanley increased their target price on Sight Sciences from $6.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Lake Street Capital raised their target price on shares of Sight Sciences from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, October 21st. Raymond James Financial set a $9.00 price target on shares of Sight Sciences in a report on Monday, January 5th. Citigroup increased their price target on Sight Sciences from $5.50 to $9.10 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Finally, UBS Group boosted their price objective on Sight Sciences from $7.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $8.30.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.